Exploring the potential of minimally invasive surgically assisted rapid maxillary expansion to transform patient outcomes

Gayıbov N., Demirbaş A. E., Kaba Y. N., Eren C., Çoban G.

JOURNAL OF CRANIO-MAXILLO-FACIAL SURGERY, vol.0, no.0, pp.0-1, 2025 (SCI-Expanded)

Abstract

Maxillary transverse deficiency (MTD) can be treated with Minimally Invasive Surgically Assisted Rapid

Maxillary Expansion (MISARME) to improve surgical outcomes in non-growing patients and increase patient

satisfaction. The purpose of this study was to compare Surgically Assisted Rapid Maxillary Expansion (SARME)

and MISARME in terms of patient outcomes, including blood loss, operation time, edema, pain, and nasal soft

tissue changes. This randomized, double-blind clinical trial was conducted on patients who underwent SARME to

treat MTD. The primary predictor variable was the type of the SARME technique: SARME or MISARME. The

primary outcome was bleeding and operation time. Secondary outcomes were postoperative pain, edema, and

nasal soft tissue changes. The study was completed with 35 patients. Blood loss and operation time were

significantly higher in the SARME (68.61 ±28.68 ml-45.27 ±2.08 min) compared to the MISARME (52.05 ±

14.03 ml-23.82 ±9.39 min) (P <.05). No statistically significant difference was observed in the mean alar base

and nasal widths at any time point within the MISARME(P <.05), while a significant difference was found in the

SARME(p >.05). The edema measured between the T1-T0 time points was significantly lower in the MISARME

compared to the SARME(P =.002). According to these results, MISARME may improve patient outcomes and

reduce undesirable changes in nasolabial soft tissues.